Ascorbic Acid
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
ASCORBIC ACID: From Vitamin C Deficiency to Non-Syndromic Esophageal Malformation
One-Sentence Summary
Ascorbic acid (Vitamin C) is an essential water-soluble micronutrient, best known as the therapeutic agent for scurvy and vitamin C deficiency, with no formal approved indication on record in Canada. The TxGNN model predicts it may be effective for Non-Syndromic Esophageal Malformation, with 0 clinical trials and 0 publications currently supporting this direction. Despite an extremely high prediction score (99.96%), this result is assessed as a likely knowledge graph false positive with no supporting mechanistic or clinical evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Vitamin C deficiency / Scurvy (established historical use; no Canada regulatory approval on record) |
| Predicted New Indication | Non-syndromic esophageal malformation |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L5 |
| Canada Market Status | Not marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from this evidence pack. Based on well-established pharmacology, ascorbic acid is an essential cofactor for prolyl and lysyl hydroxylases — the enzymes responsible for post-translational modification of collagen precursors. Deficiency leads to defective collagen cross-linking, manifest as capillary fragility, impaired wound healing, and classic scurvy. It also functions as a potent water-soluble antioxidant, supports catecholamine biosynthesis, enhances non-heme iron absorption, and modulates immune cell function.
Non-syndromic esophageal malformation is a congenital structural anomaly of the esophagus arising from disrupted embryogenesis. While ascorbic acid is theoretically involved in connective tissue formation during development, there is no established pathway by which post-natal supplementation could correct an already-formed structural malformation of the esophagus.
The internal evidence pack commentary explicitly flags this prediction as a likely false positive: the high TxGNN score most plausibly reflects topological co-occurrence of esophageal tissue nodes within the knowledge graph, rather than a genuine biological signal. This type of artifact is a known limitation of graph-based drug repurposing models when applied to rare congenital structural diseases.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
No DIN (Drug Identification Number) records found for Ascorbic Acid in the Canada Health regulatory database.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: There is a complete absence of clinical, preclinical, and mechanistic evidence supporting ascorbic acid in non-syndromic esophageal malformation; the prediction is flagged as a knowledge graph topology artifact, and no biologically plausible intervention pathway exists for a congenital structural defect using a water-soluble vitamin.
To proceed, the following is needed:
- Knowledge graph audit: verify whether the high score reflects genuine biological edges or topological noise (e.g., shared esophagus-related hub nodes)
- Mechanism of action data from DrugBank (DB00126) to formally assess any embryological relevance
- Developmental biology review: assess whether ascorbic acid influences esophageal morphogenesis in animal models
- Regulatory data: obtain Canada package insert warnings and contraindications to support basic safety profiling
Research Disclaimer: This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.